GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Upper GI Tract/Achalasia and Oesophagal Cancer: Gastroenterology | May 2026
21

Achalasia and Oesophagal Cancer: Gastroenterology | May 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated May 1, 2026

Introduction

Achalasia is a chronic oesophagal motility disorder characterised by impaired lower oesophagal sphincter relaxation and food stasis. Long-standing stasis, bacterial overgrowth, and chronic inflammation have raised concerns about an increased risk of oesophagal cancer, particularly squamous cell carcinoma. However, previous studies were small and lacked adjustment for key confounders such as smoking and alcohol. The association with adenocarcinoma has remained even more uncertain.

Problem Statement

Clinicians often struggle with two key questions:

👉 Does achalasia independently increase the risk of oesophagal cancer?

👉 Should these patients undergo structured cancer surveillance?

Existing data have been limited by small sample sizes and inadequate adjustment for major risk factors. In particular, whether achalasia contributes to adenocarcinoma risk beyond associated gastroesophageal reflux remains unclear.

Summary

This large multinational population-based study from Nordic countries provides robust evidence addressing these gaps.

Achalasia was found to be strongly associated with oesophagal squamous cell carcinoma, with nearly a 9-fold increased risk, even after adjusting for smoking and alcohol. This confirms that achalasia itself is an independent risk factor for squamous malignancy.

In contrast, achalasia showed only a modest association with oesophagal adenocarcinoma, which became non-significant after adjusting for GERD. This suggests that the observed risk of adenocarcinoma is largely driven by reflux rather than achalasia per se.

Interestingly, patients who had undergone treatment such as myotomy or dilation had an even higher risk of squamous cell carcinoma, likely reflecting longer disease duration and persistent mucosal exposure to stasis-related injury.

Overall, the study clearly differentiates cancer risk patterns in achalasia:

high and independent risk for squamous cell carcinoma

Limited and GERD-mediated risk for adenocarcinoma

These findings reinforce the need for heightened awareness of squamous cancer risk in long-standing achalasia while suggesting a more nuanced approach toward adenocarcinoma surveillance.

Related Q&A

22

Gastric Polyps: AGA Clinical Practice Update | April 2026

Introduction Gastric polyps are frequently encountered during upper gastrointestinal endoscopy and represent a heterogeneous group of lesions ranging from benign fundic gland polyps to premalignant adenomas and neuroendocrine...

23

Pediatric Eosinophilic Esophagitis- ASGE Consensus: GIE | March 2026

Introduction Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by progressive esophageal inflammation that can evolve into fibrostenotic complications such as strictures and food impaction. Endoscopy plays...

24

Dupilumab for Pediatric EoE: AJG, March 2026

Introduction Eosinophilic esophagitis (EoE) is a chronic immune-mediated oesophagal disease in children that causes feeding difficulty, vomiting, abdominal pain, dysphagia, and poor quality of life. Standard therapy often...

25

MEK Inhibitors and Gastric Precancerous Lesions: Gastroenterology | March 2026

What Are MEK Inhibitors? MEK inhibitors are targeted drugs that block the MAPK/ERK signalling pathway, specifically the MEK (mitogen-activated protein kinase kinase) enzyme. This pathway regulates cell proliferation,...

26

Eosinophilic Gastrointestinal Diseases in 2026: Gastroenterology | March 26

Introduction Eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune-mediated disorders defined by eosinophil-predominant inflammation in the GI tract. Over the past 30 years, EGIDs—especially eosinophilic esophagitis (EoE)—have risen sharply...

27

Falling Prevalence of GI Malignancy in Adults With Iron Deficiency Anaemia – IDIOM V: Endoscopy | 2026

Introduction Iron deficiency anaemia (IDA) has long been considered an important red flag for underlying gastrointestinal (GI) malignancy. However, with evolving referral patterns, widespread endoscopic access, and prior...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer